selpercatinib


( Last Updated : September 14, 2021)
Generic Name:
selpercatinib
Project Status:
Pending
Therapeutic Area:
Thyroid cancer
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
Retevmo
Project Line:
Reimbursement Review
Project Number:
PC0264-000
Call for patient/clinician input closed:
Tumour Type:
Head and Neck

Details


Manufacturer Requested Reimbursement Criteria1:
Retevmo is indicated as monotherapy for the treatment of: RET-mutant medullary thyroid cancer in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease, RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.
Fee Schedule:
Pending
Indications:
Retevmo is indicated as monotherapy for the treatment of: RET-mutant medullary thyroid cancer in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease, RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.